Long-Term Follow-Up of Renal Transplantation Due to Lupus Nephritis. Single Universitary Center Experience Lara Sanchez-Bilbao, MD – Hospital Universitario Marques de Valdecilla
9:00 AM – 11:00 AM ET
Phase I Trial of High-dose Hydroxychloroquine for the Treatment of Ambulatory Patients with Mild COVID-19: A Study in the Effects of Shifting Public Opinion on Patient Enrollment Patrick Onkka, MD – Northwestern Medicine Lake Forest Hospital
9:00 AM – 11:00 AM ET
Management of Gout After Pegloticase; Observations of US Clinical Practice from Trio Health and the American Rheumatology Network (ARN) Nehad Soloman, MD – Arizona Arthritis & Rheumatology Associates, P.C.
9:00 AM – 11:00 AM ET
Management of Gout with Pegloticase; Real-World Utilization and Outcomes from Trio Health and the American Rheumatology Network (ARN) Nehad Soloman, MD – Arizona Arthritis & Rheumatology Associates, P.C.
9:00 AM – 11:00 AM ET
Long-term Safety of Tildrakizumab in Patients with Moderate to Severe Plaque Psoriasis: Incidence of Confirmed Major Adverse Cardiovascular Events Through 3 Years (148 Weeks) from Two Phase 3 Trials Lars Iversen, MD – Aarhus University Hospital
9:00 AM – 11:00 AM ET
No Increased Risk of Liver Dysfunction from Tildrakizumab Treatment: Post Hoc Analyses of the Tildrakizumab Psoriasis Clinical Program Mark G. Lebwohl, MD – Department of Dermatology, Icahn School of Medicine at Mount Sinai
9:00 AM – 11:00 AM ET
Long-Term Efficacy and Safety of Canakinumab in Patients with Autoinflammatory Periodic Fever Syndromes – First Interim Analysis of the FMF-TRAPS-HIDS/MKD Subgroup of the RELIANCE Registry Jorg Henes, MD – University Hospital Tuebingen
9:00 AM – 11:00 AM ET
A Randomized, Double-Blind, Placebo-Controlled Study of Anakinra in Pediatric and Adult Patients with Still’s Disease Laura E. Schanberg, MD – Duke University Medical Center
9:00 AM – 11:00 AM ET
Etiologies and Management of Hemophagocytic Lymphohistiocytosis: Is It Time for an Updated Protocol and Targeted Treatments? Therese Posas-Mendoza, MD – Ochsner Clinic Foundation
9:00 AM – 11:00 AM ET
Profile of Topical Diclofenac Sodium Gel 1% (Voltaren®) Users in a United States Longitudinal Electronic Health Records Database Jess D. Edison, MD – National Capital Consortium- Walter Reed Bethesda
9:00 AM – 11:00 AM ET
WITHDRAWN
9:00 AM – 11:00 AM ET
Comparison of Nation-wide Epidemical Study on 2009 and That on 2019 Revealed That Improvement of Disease Severity and Mortality Rate May Come from Progress of Proficient Management in Patients with Relapsing Polychondritis in Japan Jun Shimizu, MD – St. Marianna University School of Medicine
9:00 AM – 11:00 AM ET
Systemic Treatment in Behçet’s Disease According to Clinical Phenotypes. Study of 111 Patients David Martinez-Lopez – Hospital Universitario Marques de Valdecilla
9:00 AM – 11:00 AM ET
Preliminary Baseline Subject Demographics and Disease Characteristics in a Phase 3 Clinical Trial of the Safety and Efficacy of Lenabasum in Dermatomyositis (DETERMINE) Victoria P. Werth, MD – University of Pennsylvania
